CytoDyn Liberated

In my last post, I ended with Scott Kelly's closing remark from the previous conference call. Today, I'll lead into this post with the same.

We need to take Dr. Kelly literally. Dr. Kelly means what he said. Leronlimab will be the next Humira. There is no doubt that this will occur. There is no doubt that CytoDyn will partner.
There is no doubt Leronlimab will be further developed over other indications and that other partnerships will be fostered with CytoDyn. As a result, opposition will build, even then. CytoDyn will continue to combat opposition on all fronts, while it progresses in all of its endeavors, in each and every indication.

CytoDyn doesn't know the word, "Quit"; She won't give up. She will do what she is destined to do which is to progress Leronlimab. She has no other way out. CytoDyn shall always be opposed, but many will come to stand with her. There is no other way out of this; as long as Leronlimab is advanced, it will be that Leronlimab advances CytoDyn, and when Leronlimab advances, her opposition is stirred up and rises. It is not a matter of "IF", but rather a matter of "WHEN". It was imminent then, it is imminent today. It can happen, and it can happen at any time.

I would greatly prefer to ignore the events of today's world because whenever I look, I'm so disheartened. But, look, we must, otherwise, who would I be other than to be disillusioned and unaware of the world in which I live. The art of discernment must be employed because all media is manipulated. As we look, we see trouble abounding, on all sides. We see injustice, criminality, perversion all abounding and stemming even from the purveyors of justice. Most of our 3 letter acronym agencies have become as trustworthy as the foreign KGB. However, we know that Money is the root of all evil, and Power is motivated by Money and Power will do anything it must, despite the cost, to garner more money. No surprise then, that we find ourselves in the midst of the shit hole we are in, as we are all peasants here, subject to the powers that be.

Therefore, our hope remains the same as it has been. Partnership with the beast. Not to become one of them, heaven forbid; but rather, that one by one, each in due time, they, through their massive motivation fueled by greed, can satisfy their monetary needs only by normalizing, by partnering with CytoDyn, by combining their failing medical solution with our enabling Leronlimab to allow them the success they require for profits while bringing Leronlimab along into the world, indication by indication and partnership by partnership.

Currently, CytoDyn's greatest problem is the clinical hold imposed by the FDA. This was a result of CytoDyn not submitting the aggregated safety data and that happened because CytoDyn's CRO Amarex did not do what they were paid tens of millions of dollars to do. They didn't do that because they were engaged in a sabotage campaign against their employing contractor CytoDyn who they utterly & truly ripped off. (Well, CytoDyn along with Sidley Austin, will see about that.) The FDA's clinical hold on Leronlimab is currently CytoDyn's number one priority in it's organization and this focus has become an all hands on deck effort. CytoDyn has a strong project team in place, led internally, by individuals with vast industry experience including senior director of clinical operations, Joe Meidling and VP of project management, Bernie Cunningham. In addition, CytoDyn has engaged with a CRO, clinical research organization which has deep experience in root sources in the areas of pharmacovigilance and safety data based management analysis. And yet even further, CytoDyn has a regulatory consulting firm that is assisting the preparation and the review of the various regulatory communications. CytoDyn provides the regulatory strategy advising group, (led by former FDA regulators), the data to work.

The FDA has been successful in slow walking CytoDyn. Yet, CytoDyn is fighting back. CytoDyn is coming clean. CytoDyn is revamping and the process is near complete. It is not just the FDA doing what they can to thwart CytoDyn; in the past month, multiple new false law suits have emerged, designed to cause new buying shareholders, new traders, to sell their shares off at losses for fear they've invested in a company plagued with litigation. The longs in CytoDyn know that these lawsuits are false advertisements for the shorts, to help and assist and coordinate with the shorts game, by causing traders to bail, in simultaneous unison with massive short attacks, thereby dramatically lowering share price. They are not true or real law suits, rather, they are called Ambulance Chaser Advertisements, but they are a technique of big pharma and big money to attack share holder value and get longs to abandon their shares in capitulation.

We know that the FDA caters to big pharma. We know big pharma has over 1,200 lobbying professionals getting their way with congress. We know that the FDA has their hands in big pharma's deep pockets. We know CytoDyn's greatest big pharma foe is Gilead. But look and see what the FDA has tried to hide for 75 years from the people's eyes and ears. Just one thing both Pfizer and FDA were trying to hide was "Indeed in May 2022, they broke the story of another section of the Pfizer documents, in which the mortality rate of fetuses and babies of women vaccinated with Pfizer’s mRNA injection was about 80 per cent." "Burying this data in this way and not alerting the world to what they found, is criminal activity yet again. This is what they do and have always done when one of their novel products begins to cause death. It is just these kinds of actions that have resulted in the billions of criminal and civil fines Big Pharma has paid in the last 20 years alone. They have done this with numerous newly launched medications such as Avandia, Bextra, Vioxx, and let’s not forget oxycodone. Many hundreds of thousands of deaths have resulted with the burying of adverse events and death data around newly launched products until they are caught, pay massive fines, and then carry on doing the same thing."

CytoDyn has a clinical Brazil trial for critical/severe Covid 19, which has been halted as a result of the clinical hold imposed by the FDA despite the fact that both this trial is held in Brazil, not the USA and also the important fact that Leronlimab has been administered for over 8 years to over 1,000 individuals without any adverse side effects.

Truly, the situation is out of hand. It is unjustly out of hand. These powers which govern the nation, and govern our way of life have become corrupt themselves. They are led by kickbacks and payment of fees. Led by their own agendas, their attacks do not stop. It is almost predictable how and when their next attack will be.

CytoDyn's way out is a partnership. CytoDyn is grooming itself exactly for that purpose. The recent 10-K has alluded to this by disclosing it's priorities: 1) Removing the clinical holds 2) Advancing NASH to a Phase 2b or 2b/3 trial 3) Exploratory Study for patients with both HIV and NASH 4) Continuing mTNBC Phase 2 trial; Exploring a Colon Cancer Phase 2 trial; Exploring a Solid Tumor Trial of various cancer types. 5) Evaluating HIV BLA resubmission; Developing long acting versions of Leronlimab; Pursuing proof of concept HIV cure with AAV 6) Covid 19 strategy review.

This means that CytoDyn's main area of focus, HIV in combination Therapy with HAART BLA is no longer the focus. Because of what Amarex has done, in their sabotage against CytoDyn, although CytoDyn will be successful in aggregating the safety data, it has become clear from the recent 10-K, that CytoDyn will not pursue the BLA as of primary importance. This means only one thing. That Whoever the NDAs are with, they are not with CytoDyn for HIV. Rather, they are with us for NASH first. Then for NASH + HIV; Then for mTNBC, Colon Cancer and other Tumors.

Prior to the special shareholders meeting, CytoDyn has gained some ground but lost a bit of it. It almost seems that we are at a stalemate. Shorts are not gaining any ground, yet, the war is costing them a bundle in interest rates which they've recently been successful in getting reduced, although it still remains high. CytoDyn has 350 million shares to be approved in the coming meeting which will give our company 350 million more reasons to win when fired by our man who is adept in war games, Cyrus Arman. When he starts his rounds of machine gun firing, shell after shell, the share price will reflect his aim. In short order thereafter, CytoDyn becomes an entity of two, then three, then four in the order stated as the 10-K's priorities. Who else will come on board with CytoDyn? Now consider, who was disqualified from continuing with CytoDyn in recent days?

Circle back, CytoDyn's biggest problem right now is the lifting of the clinical hold. Everything CytoDyn is doing is centered around that. The clinical hold MUST be lifted. The FDA is hampering our efforts, essentially putting a stand still on everything until this is resolved, thereby allowing Big Pharma the time they need to progress on their works without CytoDyn's capacity to interfere. There is no Plan B. The clinical hold must be lifted and CytoDyn has the data to get it lifted; that should be what it takes to stop their halt and suppression on CytoDyn's progress. After it is lifted, do we trust the FDA? Can we trust Gilead? Pfizer? No, they can not be trusted. They say one thing and do another. You know one thing, they follow their interests. Next hit piece may be right after next meeting. However, once clinical hold is lifted, the FDA will be out of the picture, at least for a short period. They won't be the focus any more for a bit. Shareholders will become relieved, finally, the problem is gone. Maybe there will be some peace for a change.

What happens in the next few months, when Sidley Austin finds resolution to the on going arbitration with Amarex? The only way this will be peaceful is if it ends up very successful for CytoDyn. After all, the costs CytoDyn incurred as a result of Amarex sabotage was immense, costing us even this clinical hold on leronlimab just to say a minimum. The application for the BLA that Amarex prepared is blatant obvious evidence of the sabotage against the company. Surely Sidley will use it to bring about a satisfactory resolution.

On the HIV front, the NIH has awarded multiple contracts to our Dr. Jonah Sacha, totaling over $5 million for the development of an HIV cure. If this is the case, there is at least one 3 letter acronym government agency not in it for themselves, not swayed by the deep pockets of Big Pharma. Money aimed at a cure, which the NIH believes can be fostered by the trued and tried hands of Dr. Sacha using AAV technology. If successful, the advantages of Leronlimab become a permanent part of the treated individual. In addition to becoming immune to HIV, that patient has installed in him all the benefits of having round the clock treatment with Leronlimab for life. That is great, but would make the patient unable to acquire the diseases which Leronlimab is indicated for. Surely, Big Pharma will have many problems with this, that is, unless they were sponsoring it, and given this is on the list of priorities, CytoDyn is probably in NDA on these indications for HIV other than the MDR combination indication.

On the NASH front, surely something is happening, as this is the new number one priority as per the 10-K. But, what exactly?; it has not been revealed. But it may be made known, come this special shareholder meeting. Dr. Kelly, Chris Recknor have both said frequently, that the data has been sent out world wide and that many companies have been informed of the results. Multiple NDAs are signed. The next priority is to advance NASH clinical trial to phase 2b or 2b/3 trial. With who? It won't be done on our own; so then, with who? The NASH + HIV combination indication is the next priority and it too will be with a partner who also is currently under NDA. Same questions may be asked, with who?

The mTNBC trial will be coming to a close, ending in mid September, 2022. That should be telling. We should learn a lot about the trial once that comes out. The 4th priority is to advance this trial, along with the continuation of a trial on colon cancer, then on all tumor types. We know Leronlimab was being tested along with a PD-1, or a PD-L1 inhibitor at MD Anderson Cancer Center in Texas. That should have been completed already. It is suspected that the PD-1 inhibitor was with Dolstarlimab, or Jemperli (brand name) by GSK. Therefore, it is suspected CytoDyn to partner with GSK using Jemperli or Dolstarlimab (generic) in combination therapy in mTNBC, Colon Cancer and other tumor types.

Then after all this, priority #5 is to consider HIV BLA resubmission. Wow, if we are to re-submit the BLA for HIV, by the end of year, then a whole hell of a lot of shit will be happening in the coming 4 months. But, without the lifting of the clinical hold, none of this happens, none of this is possible. It all hinges on the FDA lifting this hold. And CytoDyn knows what it must do and is executing on their plan. Wait for it, but be ready.

Here we are, 1.5 weeks away from special share holder meeting for the issuance of 350m new shares. Word of partnership can come at any time people. Tomorrow or after the meeting. I'd like to get away from using the word partnership. I'd rather say that a company is "Normalizing" with CytoDyn. That would mean that this Big Pharma company has come to terms with CytoDyn and would like to enter into an agreement where their product, along with Leronlimab are combined as the treatment for an indication. So from now on, I will say, for example, "GSK has normalized with CytoDyn".

Such a normalization is what is required to start what is necessary for CytoDyn's upward journey. The entire situation will change in an instant, at least as perceived by share holders, to CytoDyn's benefit. Who knows, the insiders, the ones who already have signed the NDAs may already know how the situation will be altered, how the tides will change once the first company normalizes with CytoDyn. Board of Directors are confident. Wheels are spinning, yes, but spinning forward. Once normalized, forward spinning wheels engage with the Earth and CytoDyn begins making forward progress. Time begins anew. The season starts afresh. With Nader out and Cyrus in, wisdom overcomes, leads and prevails.

What is about to occur can not be overestimated. It can not be over stated, it will be massive, huge, immense. It will become an overhauling of everything we know right now. And there is no stopping it because, it is meant to be. Hankster on YMB yesterday had a comment which made me understand he has the right understanding. He was discussing Dr. Kelly's new book and said the image on the book resembled a Messiah. And then he called Leronlimab the God Molecule. Well, I agree with him. The meaning of Messiah means "Annointed" and annointed means chosen. Now, Cyrus, with all that has been said about him in the conference call, and the unanimity of decision to hire him as President, by all at CytoDyn, and given what has been said about him, and by what has happened thus far, not even 2 months from his hiring 7/5/22 I think, I believe him to be very careful and of sound mind and character. Careful with money and a strategic thinker which experience in Big Pharma. He may be the annointed one, together with our annointed molecule, will propagate this ship forward. Shareholders will soon come to the realization, they have held this long for this moment, for this reason and will feel confident holding for years to come.

CytoDyn will be cleared of trials and tribulations because of Cyrus' work; all our current obstacles fall away, as his work progresses along. Many shall normalize with CytoDyn. Many are looking to normalize with CytoDyn. As each Big Pharma normalizes, they then are out of the picture, no longer a foe, no longer at odds. That company latera may become a foe, 10 or 12 years down the line, once the product returns back to generic, but for now, step right up and sign on the dotted line. CytoDyn making friends with Big Pharma. Unprecedented. We are coming upon the end of an era, and upon the beginning of a new CytoDynasty.